Pilot--Function of Smad3 in osteoblast differentiation

$0P30FY2002ARNIH

University Of Alabama At Birmingham, Birmingham AL

Investigators

Linked publications & trials

Paper 39695103 Paper 34923151 Paper 33728725 Paper 32571873 Paper 29292230 Paper 29149533 Paper 29122885 Paper 29083488 Paper 28864530 Paper 28650106 Paper 28102206 Paper 27664567 Paper 27129246 Paper 26392000 Paper 26274612 Paper 25952706 Paper 25896020 Paper 25879791 Paper 25636966 Paper 25583522 Paper 25553057 Paper 25420684 Paper 25170300 Paper 25001511 Paper 24850862 Paper 24839401 Paper 24838610 Paper 24821091 Paper 24798493 Paper 24757150 Paper 24587138 Paper 24403068 Paper 24278767 Paper 24236172 Paper 24212717 Paper 24023563 Paper 23887974 Paper 23818173 Paper 23616149 Paper 23580622 Paper 23577057 Paper 23494821 Paper 23478012 Paper 23364534 Paper 23243021 Paper 23166162 Paper 23166044 Paper 23048032 Paper 23018462 Paper 23011922 Paper 22807064 Paper 22550229 Paper 22434656 Paper 22416138 Paper 22342795 Paper 22338054 Paper 22006294 Paper 21953795 Paper 21738061 Paper 21631268 Paper 21552433 Paper 21546985 Paper 21546192 Paper 21493775 Paper 21472777 Paper 21284591 Paper 21187391 Paper 21163679 Paper 21115652 Paper 20962035 Paper 20874492 Paper 20870724 Paper 20837480 Paper 20808842 Paper 20798695 Paper 20736800 Paper 20686636 Paper 20643942 Paper 20589403 Paper 20392260 Paper 20362701 Paper 20084034 Paper 19920103 Paper 19798071 Paper 19751987 Paper 19566408 Paper 18846440 Paper 18837447 Paper 18803656 Paper 18757139 Paper 18728019 Paper 18680714 Paper 18378684 Paper 18184809 Paper 18172553 Paper 17912450 Paper 17888748 Paper 17848519 Paper 17656274 Paper 17632540

Abstract

Glucocorticoids are widely used for treatment of many diseases such as rheumatoid arthritis, pulmonary disease, and in organ transplant patients to prevent rejection. However, glucocorticoids have detrimental effects on bone, resulting in bone fractures in 50% of affected patients. The mechanism of bone los and the metabolic changes by which glucocorticoids induce the negative bone balance are not well understood. In patients with glucocorticoid-induced osteoporosis, increased bone marrow adipose tissue correlates with decreased trabecular bone volume. These observations suggest that glucocorticoids can direct bone marrow stromal stem cells to differentiate towards lineages other than the osteoblast phenotype. It has been shown recently that the glucocorticoid receptor interacts with Smad3 and inhibits TGF-beta signaling. Therefore, it is hypothesized that the glucocorticoid receptor/Smad3 interaction inhibits TGF-beta induced osteoblast differentiation and bone formation. The current proposal is intended to investigated how and when TGF-beta signaling is blocked, and what the consequences are of this interaction on osteoblast development. The objectives of this proposal are to: I. Examine the effect of glucocorticoids on TGF-beta signaling pathway in osteoblasts. The effect of glucocorticoids on TGF-beta-induced Smad3 phosphorylation, nuclear translocation, DNA binding and co-activator- Smad3 interaction will be determined. II. Determine the effect of glucocorticoids on TGF-beta-induced osteoblast differentiation marker gene expression. The expression on ALP, OPN, Cbfa1/oSF2, and type I collagen after treatment of human bone marrow stromal cells with TGF-beta and glucocorticoids will be determined by Northern analysis.

View original record on NIH RePORTER →